199 related articles for article (PubMed ID: 26417636)
1. Breast cancer and duration of tamoxifen.
Prescrire Int; 2015 Sep; 24(163):220. PubMed ID: 26417636
[TBL] [Abstract][Full Text] [Related]
2. Toremifene: an evaluation of its safety profile.
Harvey HA; Kimura M; Hajba A
Breast; 2006 Apr; 15(2):142-57. PubMed ID: 16289904
[TBL] [Abstract][Full Text] [Related]
3. The nature of tamoxifen action in the control of female breast cancer.
Kodama M; Kodama T
In Vivo; 2001; 15(4):319-25. PubMed ID: 11695224
[TBL] [Abstract][Full Text] [Related]
4. Selective estrogen-receptor modulators in 2001.
O'Regan RM; Gradishar WJ
Oncology (Williston Park); 2001 Sep; 15(9):1177-85, 1189-90; discussion 1190-4. PubMed ID: 11589065
[TBL] [Abstract][Full Text] [Related]
5. Relationship between tamoxifen use and high risk endometrial cancer histologic types.
Bland AE; Calingaert B; Secord AA; Lee PS; Valea FA; Berchuck A; Soper JT; Havrilesky L
Gynecol Oncol; 2009 Jan; 112(1):150-4. PubMed ID: 18937966
[TBL] [Abstract][Full Text] [Related]
6. Tamoxifen, hormone receptors and hormone replacement therapy in women previously treated for breast cancer: a cohort study.
Dew JE; Wren BG; Eden JA
Climacteric; 2002 Jun; 5(2):151-5. PubMed ID: 12051110
[TBL] [Abstract][Full Text] [Related]
7. Extended breast cancer treatment with an aromatase inhibitor (Letrozole) after tamoxifen: why, who and how long?
Kaufmann M; Rody A
Eur J Obstet Gynecol Reprod Biol; 2006 Jun; 126(2):146-54. PubMed ID: 16621229
[TBL] [Abstract][Full Text] [Related]
8. Chemoprevention of breast cancer: recommendations and rationale.
Berg AO;
Am J Nurs; 2003 May; 103(5):107, 109, 111, 113. PubMed ID: 12759615
[No Abstract] [Full Text] [Related]
9. The role of selective estrogen receptor modulators on breast cancer: from tamoxifen to raloxifene.
Lee WL; Cheng MH; Chao HT; Wang PH
Taiwan J Obstet Gynecol; 2008 Mar; 47(1):24-31. PubMed ID: 18400579
[TBL] [Abstract][Full Text] [Related]
10. Tamoxifen, raloxifene and the prevention of breast cancer.
Bentrem DJ; Craig Jordan V
Minerva Endocrinol; 2002 Jun; 27(2):127-39. PubMed ID: 11961504
[TBL] [Abstract][Full Text] [Related]
11. Endoxifen shows promise in breast cancer.
Cancer Discov; 2014 Feb; 4(2):OF1. PubMed ID: 24501306
[TBL] [Abstract][Full Text] [Related]
12. [Additional effect of SERM: mammary gland].
Kurebayashi J
Clin Calcium; 2004 Oct; 14(10):47-51. PubMed ID: 15577131
[TBL] [Abstract][Full Text] [Related]
13. Committee Opinion No. 601: Tamoxifen and uterine cancer.
Obstet Gynecol; 2014 Jun; 123(6):1394-1397. PubMed ID: 24848920
[TBL] [Abstract][Full Text] [Related]
14. Breast cancer risk management.
Reeder JG; Vogel VG
Clin Breast Cancer; 2007 Dec; 7(11):833-40. PubMed ID: 18269772
[TBL] [Abstract][Full Text] [Related]
15. Tamoxifen, screening and new oestrogen receptor modulators.
Neven P; Vergote I
Best Pract Res Clin Obstet Gynaecol; 2001 Jun; 15(3):365-80. PubMed ID: 11476559
[TBL] [Abstract][Full Text] [Related]
16. Understanding the BIG results: Insights from the BIG 1-98 trial analyses.
Wardley AM
Adv Ther; 2008 Dec; 25(12):1257-75. PubMed ID: 19096768
[TBL] [Abstract][Full Text] [Related]
17. Optimal systemic therapy for premenopausal women with hormone receptor-positive breast cancer.
Jankowitz RC; McGuire KP; Davidson NE
Breast; 2013 Aug; 22 Suppl 2():S165-70. PubMed ID: 24074781
[TBL] [Abstract][Full Text] [Related]
18. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.
; Thürlimann B; Keshaviah A; Coates AS; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Rabaglio M; Smith I; Wardley A; Price KN; Goldhirsch A
N Engl J Med; 2005 Dec; 353(26):2747-57. PubMed ID: 16382061
[TBL] [Abstract][Full Text] [Related]
19. Tamoxifen treatment for breast cancer and risk of endometrial cancer: a case-control study.
Swerdlow AJ; Jones ME;
J Natl Cancer Inst; 2005 Mar; 97(5):375-84. PubMed ID: 15741574
[TBL] [Abstract][Full Text] [Related]
20. Long-term toxicities of selective estrogen-receptor modulators and antiaromatase agents.
Mortimer JE; Urban JH
Oncology (Williston Park); 2003 May; 17(5):652-9; discussion 659, 662, 666 passim. PubMed ID: 12800793
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
